Entecavir is a potent nucleoside analogue for treating chronic hepatitis B (CHB). Quantitative hepatitis B surface antigen (qHBsAg) levels are predictive of response to interferon-αin CHB treatment; however, the clinical utility of qHBsAg in nucleoside/ nucleotide analogue-based CHB therapy is not fully characterized. This study assessed changes in qHBsAg in patients treated with entecavir in the Phase III study ETV-022.
Methods
This retrospective post hoc analysis included nucleoside/nucleotide-naive, hepatitis B e antigen (HBeAg)-positive patients receiving entecavir (0.5 mg daily) in ETV-022 who had samples available for qHBsAg analysis through week 48. qHBsAg, HBV DNA and alanine aminotransferase levels were assessed for the overall patient cohort, for cohorts with or without HBeAg loss or HBsAg loss by week 48, and by HBV genotype.
Results
Overall, 95 patients from ETV-022 had available samples for qHBsAg analysis through week 48. In all cohorts, 48 weeks of entecavir therapy resulted in effective HBV DNA suppression. In the overall cohort, qHB-sAg declined by -0.92 log10 IU/ml through week 48. The decline in qHBsAg was more pronounced in patients with subsequent HBeAg loss or HBsAg loss, and in patients infected with HBV genotype D or A. On-treatment qHBsAg changes did not correlate with changes in HBV DNA; no on-treatment or baseline factor was found to be predictive of HBeAg loss or HBsAg loss.
Conclusions
Through 48 weeks of entecavir therapy, qHBsAg declined predominantly in those patients who achieved seroclearance of HBeAg or HBsAg. However, unlike with interferon-α-based therapy, early qHBsAg decline was not predictive of serological response at year 1 of entecavir treatment.
References
1.
LiangX., BiS., YangW.Epidemiological serosurvey of hepatitis B in China – declining HBV prevalence due to hepatitis B vaccination. Vaccine2009; 27: 6550–6557.
2.
World Health Organization.Hepatitis B. World Health Organization Fact Sheet 204.Geneva: World Health Organization2012.
3.
McMahonB.J.Epidemiology and natural history of hepatitis B. Semin Liver Dis2005; 25Suppl 1: 3–8.
4.
KowdleyK.V., WangC.C., WelchS., RobertsH., BrosgartC.L.Prevalence of chronic hepatitis B among foreign-born persons living in the United States by country of origin. Hepatology2012; 56: 422–433.
5.
FattovichG., BortolottiF., DonatoF.Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol2008; 48: 335–352.
6.
LiawY.F., KaoJ.H., PiratvisuthT.Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int2012; 6: 531–561.
7.
European Association for the Study of the Liver.EASL Clinical Practice Guidelines: management of chronic hepatitis B virus infection. J Hepatol2012; 57: 167–185.
ChuC.M., LiawY F.Hepatitis B surface antigen seroclearance during chronic HBV infection. Antivir Ther2010; 15: 133–143.
10.
PerrilloR.Editorial: measurement of HBsAg concentration during antiviral therapy of hepatitis B: who, when, and why. Am J Gastroenterol2011; 106: 1774–1776.
11.
KwonH., LokA.S.Hepatitis B therapy. Nat Rev Gastroenterol Hepatol2011; 8: 275–284.
12.
LiawY.F., SheenI.S., ChenT.J., ChuC.M., PaoC.C.Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study. Hepatology1991; 13: 627–631.
13.
GishR.G., ChangT.T., LaiC.L.Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naive HBeAg-positive patients with chronic hepatitis B. J Viral Hepat2010; 17: 16–22.
14.
HeathcoteE.J., MarcellinP., ButiM.Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology2011; 140: 132–143.
15.
FlinkH.J., van ZonneveldM., HansenB.E., de ManR.A., SchalmS.W., JanssenH.L.Treatment with peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol2006; 101: 297–303.
16.
ErhardtA., BlondinD., HauckK.Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut2005; 54: 1009–1013.
17.
WaiC.T., ChuC.J., HussainM., LokA.S.HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology2002; 36: 1425–1430.
18.
YuenM.F., WongD.K., SablonE.HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects. Hepatology2004; 39: 1694–1701.
19.
Mommeja-MarinH., MondouE., BlumM.R., RousseauF.Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology2003; 37: 1309–1319.
20.
SonneveldM.J., ZoutendijkR., JanssenH.L.Hepatitis B surface antigen monitoring and management of chronic hepatitis B. J Viral Hepat2011; 18: 449–457.
21.
LiangT.J.Hepatitis B: the virus and disease. Hepatology2009; 49Suppl 5: S13–S21.
22.
ZoulimF.Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection. Antiviral Res2004; 64: 1–15.
23.
ViganòM., LamperticoP.Clinical implications of HBsAg quantification in patients with chronic hepatitis B. Saudi J Gastroenterol2012; 18: 81–86.
24.
FungJ., LaiC.L., YoungJ.Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment. Am J Gastroenterol2011; 106: 1766–1773.
25.
LeeM.H., Lee daM., KimS.S., CheongJ.Y., ChoS.W.Correlation of serum hepatitis B surface antigen level with response to entecavir in naive patients with chronic hepatitis B. J Med Virol2011; 83: 1178–1186.
26.
LeeJ.M., AhnS.H., KimH.S.Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir. Hepatology2011; 53: 1486–1493.
27.
WongG.L., WongV.W., ChanH.Y.Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years. Aliment Pharmacol Ther2012; 35: 1326–1335.
28.
ShinJ.W., JungS.W., ParkB.R.Prediction of response to entecavir therapy in patients with HBeAg-positive chronic hepatitis B based on on-treatment HBsAg, HBeAg and HBV DNA levels. J Viral Hepat2012; 19: 724–731.
29.
SongJ.C., MinB.Y., KimJ.W.Pretreatment serum HBsAg-to-HBV DNA ratio predicts a virologic response to entecavir in chronic hepatitis B. Korean J Hepatol2011; 17: 268–273.
30.
WooG., TomlinsonG., NishikawaY.Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology2010; 139: 1218–1229.
31.
ChangT.T., LaiC.L., KewY.S.Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology2010; 51: 422–430.
32.
OnoA., SuzukiF., KawamuraY.Long-term continuous entecavir therapy in nucleos(t)ide-naive chronic hepatitis B patients. J Hepatol2012; 57: 508–514.
33.
TenneyD.J., RoseR.E., BaldickC.J.Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology2009; 49: 1503–1514.
34.
ChangT.T., GishR.G., de ManR.A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med2006; 354: 1001–1010.
35.
GishR.G., LokA.S., ChangT.T.Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology2007; 133: 1437–1444.
36.
Van BoemmelF., BockF.J., Hensel-WiegelK.Kinetics of HBsAg levels in patients with chronic hepatitis B virus (HBV) infection during up to 4 years of treatment with acyclic nuecleotide analogs. Hepatology2009; 50Suppl 4: 522A.
37.
WursthornK., JungM., RivaA.Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology2010; 52: 1611–1620.
38.
SonneveldM.J., RijckborstV., BoucherC.A., HansenB.E., JanssenH.L.Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology2010; 52: 1251–1257.
39.
ZoutendijkR., HansenB.E., van VuurenA.J., BoucherC.A., JanssenH.L.Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss. J Infect Dis2011; 204: 415–418.
40.
ReijndersJ.G., RijckborstV., SonneveldM.J.Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir. J Hepatol2011; 54: 449–454.
41.
ZoulimF., CarosiG., GreenbloomS.Quantification of HBsAg in nucleos(t)ide-naive patients treated for chronic hepatitis B with entecavir or entecavir plus tenofovir in the BE-LOW study. J Viral Hepat2012; 19: 2.
42.
WongD.K., YuenM.F., NgaiV.W., FungJ., LaiC.L.One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels. Antivir Ther2006; 11: 909–916.
43.
PerrilloR.P., LaiC.L., LiawY.F.Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology2002; 36: 186–194.
44.
NguyenT., ThompsonA.J., BowdenS.Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol2010; 52: 508–513.
45.
MarcellinP., HeathcoteE.J., ButiM.HBsAg kinetics in patients with chronic hepatitis B (CHB) treated with tenofovir disoproxil fumarate (TDF) for up to 4 years. J Hepatol2011; 54: S297.
46.
GishR.G., ChangT.T., LaiC.L.Loss of HBsAg in nucleoside-naive HBeAg(+) chronic hepatitis B patients following treatment with entecavir or lamivudine: evaluation of HBV genotypes. Hepatology2009; 50: 487A.
47.
MarcellinP., GaneE.J., ButiM.Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet2013; 381: 468–475.
